Paladin Energy Ltd: June 2025 Quarter Results
PERTH, Australia, July 22, 2025 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) ('Paladin' or the 'Company') advises that it has released its quarterly activities and cashflow reports for the period ended 30 June 2025 ('June 2025 Quarter Results').
The Company has also released an accompanying presentation on the June 2025 Quarter Results.
The quarterly activities and cashflow reports and presentation are available on Paladin's website (https://www.paladinenergy.com.au/investors/asx-announcements/).
For further information contact:
About Paladin
Paladin Energy Ltd (ASX:PDN TSX: PDN OTCQX:PALAF) is a globally significant independent uranium producer with a 75% ownership of the world-class long life Langer Heinrich Mine located in Namibia. In late 2024 the Company acquired Fission Uranium Corp. in Canada, resulting in a dual-listing on the both the ASX and TSX. With the integration of Fission's operations, the Company now owns and operates an extensive portfolio of uranium development and exploration assets across Canada, which include the Patterson Lake South (PLS) project in Saskatchewan and the Michelin project in Newfoundland and Labrador. Paladin also owns uranium exploration assets in Australia. Through its Langer Heinrich Mine, Paladin is delivering a reliable uranium supply to major nuclear utilities around the world, positioning itself as a meaningful contributor to baseload energy provision in multiple countries and contributing to global decarbonisation.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Kinross announces sale of shares of White Gold
(All dollar amounts are expressed in Canadian dollars, unless otherwise noted.) TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — Kinross Gold Corporation ('Kinross' or the 'Company') (TSX: K, NYSE: KGC) announced today that it has sold an aggregate of 23,681,160 common shares of White Gold Corp. ('White Gold') representing all of the common shares held by Kinross. The shares represent approximately 12% of the outstanding White Gold common shares. The shares were sold at an average sales price of $0.29 (excluding commission), representing an aggregate sale price of $6,869,905.51. A copy of the early warning report filed by Kinross in connection with the investment will be available on White Gold's profile on SEDAR+ at . Alternatively, you may contact Luke Crosby, Senior Vice President, General Counsel and Corporate Secretary at 647-788-4478 to obtain a copy of the report. Kinross is organized under the laws of the Province of Ontario and its head office is located at 25 York Street, 17th Floor, Toronto, Ontario M5J 2V5. White Gold's head office is located at 82 Richmond Street East, Toronto, Ontario, M5C 1P1. About Kinross Gold Corporation Kinross is a Canadian-based global senior gold mining company with operations and projects in the United States, Brazil, Mauritania, Chile and Canada. Our focus is on delivering value based on the core principles of responsible mining, operational excellence, disciplined growth, and balance sheet strength. Kinross maintains listings on the Toronto Stock Exchange (symbol: K) and the New York Stock Exchange (symbol: KGC). Media Contact Samantha Sheffield Director, Corporate Communications phone: 416-365-3034 Investor Relations Contact David Shaver Senior Vice-President, Investor Relations & Communications phone: 647-365-2854 investorrelations@ Source: Kinross Gold Corporation
Business Wire
2 hours ago
- Business Wire
Accord Announces Banking Facility Update
TORONTO--(BUSINESS WIRE)--Accord Financial Corp. ('Accord' or the 'Company') (TSX – ACD) today announced that it has reached an agreement with its lending syndicate on a short-term extension of its main credit facility from July 26, 2025, to August 8, 2025. The Company and its lenders are in discussions relating to an amendment to the credit facility which is expected to extend the maturity date to December 2025, and the extension will provide additional time for such amendment to be finalized. About Accord Financial Corp. Accord Financial is one of North America's most dynamic commercial finance companies providing fast, versatile financing solutions for including asset-based lending, factoring, inventory finance, equipment leasing, trade finance and film/media finance. By leveraging our unique combination of financial strength, deep experience and independent thinking, we craft winning financial solutions for small and medium-sized businesses, simply delivered, so our clients can thrive. Forward-Looking Statements This news release contains certain 'forward-looking statements', and certain 'forward-looking information' as defined under applicable Canadian securities laws. Forward-looking statements can generally be identified by the use of forward-looking terminology such as 'may', 'will', 'expect', 'intend', 'estimate', 'anticipate', 'believe', 'continue', 'plans' or similar terminology. Forward-looking statements in this news release include, but are not limited to, statements, management's beliefs, expectations or intentions regarding the financial position of the Company, and the extension of the Company's credit facilities. Forward-looking statements are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements are subject to various risks and uncertainties including the fact that there is no assurance on the ability of the Company to enter into arrangements with its lenders to further extend the maturity date of its credit facilities on reasonable terms, or at all, and the Company's overall liquidity and capital resource position and its ability to repay its debt obligations when due, and those risks identified in the Accord's periodic filings with Canadian securities regulators. See Accord's most recent annual information form and most recent management's discussion and analysis of results of operations and financial condition for a detailed discussion of the risk factors affecting Accord. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units
Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — AI Inc. (the 'Company' or 'Treatment') (CSE: TRUE; OTC: TREIF; 939: FRA) is pleased to announce that due to strong inbound interest from new and existing investors, it is undertaking a non-brokered private placement of up to C$3 million of a combination of special warrants of the Company (each, a 'Special Warrant') at a price of C$0.50 per Special Warrant and units of the Company (each, a 'Unit') at a price of C$0.50 per Unit ('Offering'). Each Unit shall consist of one common share of the Company (a 'Share') and one common share purchase warrant (each, a 'Warrant'). Each Warrant shall entitle the holder thereof to acquire one Share at a price of C$0.75 per Share for a period of 12 months following the date of issuance of the Warrants. Each Special Warrant will automatically convert, for no additional consideration, into one Unit on the date (the 'Conversion Date') that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the 'Prospectus Supplement') qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date. The Company will use its commercially reasonable efforts to file the Prospectus Supplement to qualify the distribution of the Shares and Warrants issuable upon conversion of the Special Warrants within 60 days of the closing of the Offering (not including the date of closing). The Company may pay a finder's fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants (the 'Broker Warrants') equal up to 8% of the number of Special Warrants and/or Units sold under the Offering. Each Broker Warrant will entitle the holder to purchase one Share (a 'Broker Share') at an exercise price of C$0.75 per Broker Share for a period of 12 months from the date of issuance of the Broker Warrants. The Company intends to use the proceeds raised from the Offering for working capital purposes. The Offering is expected to close on or before August 18, 2025. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. The Special Warrants, Broker Warrants (and securities underlying the Broker Warrants) and Units issued on the closing of the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. Prior to the filing of the Prospectus Supplement and the automatic conversion of the Special Warrants, the Units, and the securities underlying such Units, issuable upon conversion of the Special Warrants will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. The securities being referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the U.S. or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About AI Inc. AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: or email: info@ m FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@ For media inquiries, contact: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
